Harnessing immune checkpoint trial data in pediatric cancer

被引：0
|
作者：
Neeson, Paul J. [1 ,2 ]
Ekert, Paul G. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] Murdoch Childrens Res Inst, Parkville, Vic, Australia
[4] UNSW Sydney, Childrens Canc Inst, Lowy Canc Res Ctr, Kensington, NSW, Australia
[5] UNSW Sydney, Sch Clin Med, UNSW Med & Hlth, Sydney, NSW, Australia
来源：
NATURE CANCER | 2023年 / 4卷 / 04期
关键词：
SINGLE-ARM; OPEN-LABEL; PEMBROLIZUMAB; PROFILE; TUMOR;
D O I：
10.1038/s43018-023-00540-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The response rates of pediatric cancers to immune checkpoint inhibitor therapies are disappointingly low, particularly when compared to the remarkable impact of these drugs in many adult cancers. A new study leverages clinical trial data to identify biomarkers that might improve patient selection in future clinical trials.
引用
收藏
页码：444 / 446
页数：3
相关论文
共 50 条
  • [1] Harnessing immune checkpoint trial data in pediatric cancer
    Paul J. Neeson
    Paul G. Ekert
    Nature Cancer, 2023, 4 : 444 - 446
  • [2] Trial watch: Immune checkpoint blockers for cancer therapy
    Vanpouille-Box, Claire
    Lhuillier, Claire
    Bezu, Lucillia
    Aranda, Fernando
    Yamazaki, Takahiro
    Kepp, Oliver
    Fucikova, Jitka
    Spisek, Radek
    Demaria, Sandra
    Formenti, Silvia C.
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2017, 6 (11):
  • [3] IDO-BASED IMMUNE CHECKPOINT BLOCKADE FOR PEDIATRIC BRAIN TUMORS: PRECLINICAL DATA AND CLINICAL TRIAL DESIGN
    Johnson, Theodore
    Li, Minghui
    Gamble, Denise
    Macdonald, Tobey
    Munn, David
    PEDIATRIC BLOOD & CANCER, 2015, 62 : 104 - 104
  • [4] Harnessing genetic interactions for prediction of immune checkpoint inhibitors response signature in cancer cells
    Liu, Mingyue
    Zhao, Zhangxiang
    Wang, Chengyu
    Sang, Shaocong
    Cui, Yanrui
    Lv, Chen
    Yang, Xiuqi
    Zhang, Nan
    Xiong, Kai
    Chen, Bo
    Dong, Qi
    Liu, Kaidong
    Gu, Yunyan
    CANCER LETTERS, 2024, 594
  • [5] Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
    Kim, Nayoung
    Lee, Dong-Hee
    Choi, Woo Seon
    Yi, Eunbi
    Kim, HyoJeong
    Kim, Jung Min
    Jin, Hyung-Seung
    Kim, Hun Sik
    BMB REPORTS, 2021, 54 (01) : 44 - 58
  • [6] Harnessing the power of big data to advance pediatric cancer care
    Morozova, Olena
    Newton, Yulia
    Cline, Melissa
    Yip, Stephen
    Rao, Arjun
    Stuart, Josh
    Goldstein, Ted
    Salama, Sofie
    Deyell, Rebecca
    Rassekh, S. Rod
    Haussler, David
    CANCER RESEARCH, 2016, 76
  • [7] Harnessing Immune Checkpoint Inhibitors Against Gastric Cancer: Charting the Course to Expanded Therapeutic Benefit
    Chung, Dang Thanh
    Tung, Dang Son
    Dung, Tran Ngoc
    BIOMEDICAL RESEARCH AND THERAPY, 2024, 11 (04): : 6305 - 6325
  • [8] Harnessing immune responses in prostate MMRd tumors treated with immune checkpoint blockade
    Badia, Marcel Arias
    Fan, Zenghua
    Lwin, Yee May
    Chen, Peixi
    Srinath, Aahir
    Fong, Lawrence
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy
    Fatima, Shadma
    Ma, Yafeng
    Safrachi, Azadeh
    Haider, Sana
    Spring, Kevin J.
    Vafaee, Fatemeh
    Scott, Kieran F.
    Roberts, Tara L.
    Becker, Therese M.
    de Souza, Paul
    CANCERS, 2022, 14 (07)
  • [10] Harnessing the gut microbiome to modulate immune checkpoint blockade response in triple-negative breast cancer
    Clear, Kenysha Y. J.
    Wilson, Adam S.
    Stirling, Elizabeth R.
    Tsai, Yu-Ting
    Payne, Valerie
    Soto-Pantoja, David R.
    Cook, Katherine L.
    CANCER RESEARCH, 2024, 84 (06)
12345